Annovis Bio, Inc.
Symbol: ANVS (NYSE)
0.00
▼ (-100.00%) -2.310
Company Description:
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
Key Stats
- Today's Open: $0
- Today's High: $0
- Today's Low: $0
- Today's Volume: 0
- Yesterday Close: $2.31
- Yesterday High: $2.4
- Yesterday Low: $2.26
- Yesterday Volume: 170.06K
- Last Min Volume: 0
- Last Min High: $0
- Last Min Low: $0
- Last Min VWAP: $0
Company Profile
- Name: Annovis Bio, Inc.
- Website: https://www.annovisbio.com
- Listed Date: 2020-01-29
- Location: MALVERN, PA
- Market Status: Active
- CIK Number: 0001477845
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $45.01M
- Round Lot: 100
- Outstanding Shares: 19.49M
- Asset Type: CS
RECENT FILINGS FOR ANVS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-03 | 4 | View |
| 2025-08-20 | 4 | View |
| 2025-08-15 | 8-K | View |
| 2025-08-12 | 10-Q | View |
| 2025-08-12 | 8-K | View |
| 2025-06-23 | 8-K | View |
| 2025-06-20 | 8-K | View |
| 2025-06-18 | 4 | View |
| 2025-06-16 | 4 | View |
| 2025-06-11 | 4 | View |
| 2025-06-05 | 4 | View |
| 2025-06-02 | 4 | View |
| 2025-05-16 | 3 | View |
| 2025-05-13 | 8-K | View |
| 2025-05-13 | 10-Q | View |
| 2025-05-12 | SCHEDULE 13G/A | View |
| 2025-05-01 | ARS | View |
| 2025-05-01 | DEFA14A | View |
| 2025-04-30 | DEF 14A | View |
| 2025-03-27 | 8-K | View |
Latest News on ANVS